Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
bioAffinity Technologies announced it will participate in the Lung Cancer Initiative of North Carolina’s 'Battle of the Blues' event on November 5, 2026. The company will highlight its CyPath Lung noninvasive diagnostic test alongside physicians and patient advocates to promote early lung cancer detection during National Lung Cancer Awareness Month.
Quanome Technologies' subsidiary XDT Infrastructure received a $13.5 million milestone prepayment from an enterprise customer for dedicated AI inference services. This payment is part of a previously announced 60-month agreement with a total commitment value exceeding $100 million and will fund the procurement of GPU servers and infrastructure build-out.
First Eagle Private Credit Fund disclosed its Schedule of Investments and Unfunded Commitments as of September 30, 2026. The filing provides a detailed list of the fund's portfolio holdings across various industries, including Aerospace & Defense, Air Freight & Logistics, and Automobile Components, along with their fair values and interest rates.
Evolution Metals & Technologies Corp. submitted a capability statement in response to a U.S. Army Sources Sought notice for rare earth magnets used in small drone motors. The company currently produces one of the specified magnet grades (N42SH) at its facility in Pohang, South Korea, and plans to expand annual production capacity there from 1,000 to 10,000 metric tons.
FedEx Corporation is providing supplemental historical financial information to reflect a change in its fiscal year end from May 31 to December 31 and the completed spin-off of its FedEx Freight business. The filing also details a realignment of its internal reporting structure into two new reportable segments: Express U.S. Domestic and Express International.
Macquarie Infrastructure Fund, L.P. entered into an amendment to its investment advisory agreement where its adviser, Macquarie Wealth Advisers, LLC, agreed to waive management fees entirely through November 30, 2027, and partially through November 30, 2028. Additionally, the adviser extended the expense limitation and reimbursement period from one year to three years from the fund's initial closing date.
The E.W. Scripps Company raised its full-year 2026 political advertising revenue guidance to $275 million and completed a workforce reduction of 431 employees. The company expects to achieve $100 million in annual run-rate savings by year-end as part of a transformation plan to drive EBITDA growth through 2028.
Dropbox announced a 9% reduction of its global workforce to align investments with product priorities, estimating cash expenditures of $27 million to $33 million. Additionally, the company provided a preliminary Q3 2026 update stating results are expected to be in-line with or above previous guidance, and announced that CTO Ali Dasdan will step down effective November 18, 2026.
Contango Silver & Gold provided a 2026 field season update, reporting that drilling at the Kitsault Project reached 56,492 meters, exceeding the 40,000-meter target. The company also completed infrastructure work at the Johnson Tract Project ahead of schedule and commenced a new drilling program at the Lucky Shot Project. Management expects to release assay results over the next few months and update the Kitsault mineral resource estimate in the first half of 2027.
MetaVia announced that an abstract for its Phase 1 clinical trial of DA-1726, a dual GLP-1 and glucagon receptor agonist, has been accepted for an oral presentation at the Precision Liver Symposium 2026. The presentation, scheduled for November 4, 2026, will highlight data regarding weight loss and reduction in MRI-PDFF (liver fat) in patients. While the filing mentions previous trial findings, it does not disclose the specific new data points or results that will be presented at the upcoming conference.
ACM Research announced preliminary unaudited revenue for the third quarter of 2026, expected to be between $360 million and $365 million, representing 34% to 36% year-over-year growth. The company also reported expected total shipments of $335 million to $340 million for the same period. The update coincides with the release of financial results by its principal operating subsidiary, ACM Shanghai.
Palvella Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for QTORIN™ 3.9% rapamycin anhydrous gel and granted it Priority Review. The application seeks approval for the treatment of microcystic lymphatic malformations, with a PDUFA target action date set for February 28, 2027.
Genprex announced that research from its sponsored collaboration with Meharry Medical College will be presented at the Gerontological Society of America 2026 Annual Scientific Meeting. The research explores the role of the TUSC2 gene, used in the company's lead candidate REQORSA, in cellular resilience and molecular processes associated with aging. This data may inform potential future therapeutic applications for REQORSA beyond its current focus on oncology and diabetes.
Virtuix Holdings announced it expects to report strong revenue growth for Q2 FY2027, driven by Omni One sales following its June launch for Meta Quest. The company scheduled its formal earnings conference call for November 16, 2026, to discuss these preliminary results and updates on its defense and healthcare initiatives.
Ellington Financial Inc. announced an estimated book value per share of common stock of $13.53 as of September 30, 2026. The estimate includes the impact of a previously announced monthly dividend of $0.13 per share payable on October 30, 2026.
Cayson Acquisition Corp entered into a Strategic Cooperation and Services Agreement with Prisma Global Holding Limited to assist in securing up to $1 million in working capital loans and introducing potential PIPE financing sources of up to $18 million. Prisma will receive a 10% fee for committed loans and a mutually agreed fee for PIPE introductions, plus expense reimbursements. The agreement aims to support the company's operations and financing needs ahead of its initial business combination.
Prospect Capital Corporation provided preliminary financial estimates for the quarter ended September 30, 2026, reporting an estimated net investment income of approximately $76 million. The company also estimated its common equity net asset value at $2.9 billion and total assets at approximately $6.0 billion, with a debt-to-asset ratio of 25%.
Sangamo Therapeutics filed amended monthly operating reports (MORs) for July and August 2026, along with a new MOR for September 2026, as part of its ongoing Chapter 11 bankruptcy proceedings. The reports provide updated cash balances, receipts, and disbursements required by the Bankruptcy Court but are not prepared in accordance with GAAP. The company's common stock was recently delisted from Nasdaq and currently trades on the OTC Expert Market.
TechTarget provided a preliminary revenue update for the nine-month period ending September 30, 2026, reporting an underlying revenue decline of 1.6% compared to the prior year. The company attributed the decrease to market volatility and enterprise technology customers prioritizing AI investments over marketing and sales support. Full quarterly results under US GAAP are scheduled for release on November 6, 2026.
Atrium Therapeutics announced the first patient has been dosed in its Phase 1/2 Corventis clinical trial evaluating ATR 1072 for the treatment of PRKAG2 syndrome. This represents the first interventional clinical trial for this rare genetic cardiomyopathy, with initial proof-of-concept data expected in the second half of 2027.
Artiva Biotherapeutics is halting all development of its lead cell therapy candidate AlloNK (AB-101) and implementing a 94% workforce reduction after clinical data failed to meet durability thresholds and two patient deaths occurred. The company has engaged Leerink Partners to explore strategic alternatives, including a potential merger, sale, or liquidation, while reporting a preliminary cash balance of $319.1 million.
CDT Equity entered into an evaluation agreement with Manoira Corporation to analyze clinical-stage compounds AZD1656 and AZD5904 for potential use in animal health products. As part of the arrangement and other corporate obligations, the company issued shares to Manoira to settle a $195,000 payment, as well as shares to a service provider and former CEO Dr. Andrew Regan for severance.
Nova Minerals has secured final permits from the Alaska Department of Natural Resources for its Alaska antimony project, authorizing mining, processing, and refining activities. The project is supported by $43.4 million in Department of War funding and is targeting commercial production of military-grade antimony trisulfide in 2027.
GrafTech International Ltd. finalized estimates for its previously announced permanent closure of its manufacturing facility in Monterrey, Mexico. The company expects to incur total non-cash charges of $25 million to $35 million, including $12.3 million in fixed asset write-offs, while maintaining its estimate of $20 million to $25 million in one-time cash expenditures.
Flash Sports & Media Holdings reported preliminary unaudited Q3 2026 revenue of approximately $6.2 million, a significant increase from $44,318 in Q2 2026 driven by the Lanka Premier League season. The company also announced strategic expansions including plans for new T20 leagues in Malaysia and Zimbabwe and a title sponsorship for the Switzerland men’s national cricket team.
Maplebear Inc. (Instacart) announced it will wind down its Caper Cart operations to re-align resources toward strategic priorities, with completion expected by Q2 2027. The company expects to incur pre-tax restructuring charges between $55 million and $80 million, including asset impairments, contract termination fees, and employee severance. Management intends to reinvest the resulting savings into strategic growth initiatives.
Citius Pharmaceuticals' subsidiary, Citius Oncology, reported preliminary fiscal fourth quarter 2026 operational metrics for its drug LYMPHIR. The company saw a 120% increase in unit sales to wholesalers (792 units) and expanded its institutional reach to 54 ordering centers as it works toward a goal of 100 priority institutions by year-end.
Citius Oncology reported preliminary fiscal fourth quarter 2026 operational metrics for its drug LYMPHIR, showing a 120% increase in unit sales to U.S. wholesalers compared to the prior quarter. The company reached 792 units sold to wholesalers and expanded its institutional reach to 54 prescribing centers as of late October.
Jazz Pharmaceuticals provided a preliminary update on its Q3 2026 financial results, estimating a $755 million pre-tax charge for acquired in-process research and development (IPR&D) related to its acquisition of Actio Biosciences. This non-deductible charge is expected to have an unfavorable impact of approximately $11.00 on both GAAP and non-GAAP adjusted earnings per share for the quarter.
TriLinc Global Impact Fund provided a portfolio update as of September 30, 2026, reporting total portfolio assets of approximately $283 million. The company has funded $1.210 billion in aggregate investments to date across 103 borrower companies globally, with $925.2 million in full repayments received.